hOTC Enhancer Vectors for Stable Liver Transgene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies face challenges in achieving stable and robust expression of transgenes in liver cells, particularly due to difficulties in cell type specificity, transduction efficacy, and level and duration of expression.
Innovation Solution
The use of polynucleotides comprising a human ornithine transcarbamylase (hOTC) enhancer operably linked to a liver-specific promoter, such as the human alpha 1-antitrypsin (hAAT) promoter, with optional introns and polyadenylation signals, to enhance transgene expression in liver cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional promoters and regulatory elements are used, then the vector structure is simple, but stable and robust transgene expression in liver cells cannot be achieved
Solution Approach 1:
The patent combines multiple regulatory elements (hOTC enhancer, liver-specific promoter, introns, polyadenylation signals) into a single integrated polynucleotide construct. This merging of functional elements works synergistically to achieve stable and robust transgene expression in liver cells, resolving the contradiction by consolidating complexity into a unified expression cassette that reliably produces therapeutic protein.
Solution Approach 2:
The polynucleotide construct functions as a composite regulatory system where different DNA elements (enhancer, promoter, intron, terminator) with distinct functions are assembled together. Each element contributes a specific function: the hOTC enhancer provides transcriptional activation, the liver-specific promoter provides cell-type specificity, introns enhance expression stability, and polyadenylation signals ensure proper mRNA processing. This composite structure achieves reliable expression that individual elements cannot accomplish alone.
2Adaptability or versatility
If liver-specific promoters are used to achieve cell type specificity, then transgene expression is targeted to liver cells, but transduction efficacy and expression levels are insufficient
Solution Approach 1:
The patent merges a liver-specific promoter with a potent enhancer element (hOTC enhancer) to create a synergistic regulatory system. The promoter provides the necessary liver cell specificity for targeted expression, while the enhancer dramatically amplifies transcriptional activity. This combination resolves the contradiction by maintaining cell-type specificity while achieving high expression levels sufficient for therapeutic efficacy.
Solution Approach 2:
The invention changes the transcriptional parameter by introducing strong enhancer sequences upstream of the liver-specific promoter. This parameter change (adding enhancer activity) transforms the moderate expression level of a promoter alone into high-level expression, while the promoter's specificity for liver cells remains unchanged. The result is a construct that is both liver-specific and highly productive.
3Stability of the object's composition
If multiple regulatory elements are added to enhance expression, then transgene expression stability improves, but the difficulty of achieving robust expression persists due to improper element configuration
Solution Approach 1:
The patent employs extensively characterized and pre-validated regulatory elements with known functions and optimal configurations. The hOTC enhancer, liver-specific promoters, introns, and polyadenylation signals have been previously studied and optimized for liver gene expression. This preliminary characterization allows the elements to be assembled into a functional construct without extensive trial-and-error, resolving the contradiction by using pre-tested components that stabilize expression while minimizing configuration difficulties.
Solution Approach 2:
The intron elements serve as intermediaries between the promoter and transgene coding sequence. These intronic sequences mediate several functions including enhancing mRNA processing, increasing transcript stability, and improving translation efficiency. By inserting these intermediary elements in specific positions within the polynucleotide construct, the patent achieves stable and robust expression while following established structural patterns that reduce the complexity of construct design.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention is directed to polynucleotides and vectors for the expression of a transgene in liver cells. The present invention is also directed to various uses of the polynucleotides and vectors, such as in gene therapy, and methods for expressing the transgene from the polynucleotides and vectors in liver cells. In particular the invention relates to polynucleotides and vectors comprising a human ornithine transcarbamylase (hOTC) enhancer and a liver specific promoter. In particular embodiments the transgene is ornithine transcarbamylase and the vectors are used in the treatment or prevention of ornithine transcarbamylase deficiency or hyperammonemia.